Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

32.01
-0.0600-0.19%
Post-market: 32.200.1900+0.59%19:59 EDT
Volume:3.39M
Turnover:109.42M
Market Cap:3.60B
PE:-27.76
High:33.16
Open:32.16
Low:31.28
Close:32.07
Loading ...

Viking Therapeutics Q1 GAAP EPS $(0.41) Misses $(0.34) Estimate

Benzinga
·
24 Apr

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
24 Apr

Viking Therapeutics Q1 Operating Expenses USD 55.469 Million

THOMSON REUTERS
·
24 Apr

Viking Therapeutics options imply 8.5% move in share price post-earnings

TIPRANKS
·
24 Apr

Viking Therapeutics Inc : Oppenheimer Cuts Target Price to $100 From $164

THOMSON REUTERS
·
23 Apr

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Zacks
·
21 Apr

Viking Therapeutics to Report Q1 Earnings: What's in the Cards?

Zacks
·
21 Apr

Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic's Competition Grows -- Barrons.com

Dow Jones
·
19 Apr

H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data

TipRanks
·
18 Apr

JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics

TipRanks
·
18 Apr

Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know

Zacks
·
18 Apr

Viking Therapeutics Price Target Maintained With a $102.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Apr

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Motley Fool
·
18 Apr

Shares of Some Obesity Drug Developers Fall After Eli Lilly's Pill Leads to Weight Loss in Late-Stage Trial

THOMSON REUTERS
·
17 Apr

U.S.-Listed Shares of Novo Nordisk Down 7.9%, Viking Therapeutics Down 3.9%, Amgen Down 3.4%

THOMSON REUTERS
·
17 Apr

Lilly's Weight-Loss Pill Shocks Wall Street

GuruFocus.com
·
17 Apr

BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial

Reuters
·
17 Apr

Eli Lilly's stock soars as successful trial of weight-loss pill is a game changer

Dow Jones
·
17 Apr

Shares of Obesity Drug Developer Viking Therapeutics Falls 5.3% Premarket After Eli Lilly's Pill Leads to Weight Loss in Late-Stage Trial

THOMSON REUTERS
·
17 Apr

Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

PR Newswire
·
17 Apr